RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results Portfolio News / Karina Tin March 10, 2022 RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results Read More »
NGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcoming 2022 AACR Annual Meeting Portfolio News / Karina Tin March 8, 2022 NGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcoming 2022 AACR Annual Meeting Read More »
A2 Bio’s Activator-blocker CAR-T Cell Therapies Show Early Promise in Solid Cancers Portfolio News / Karina Tin March 4, 2022 A2 Bio’s Activator-blocker CAR-T Cell Therapies Show Early Promise in Solid Cancers Read More »
A2 Bio Publishes Key Preclinical Findings Demonstrating Potential of Its Highly Selective Tmod™ Cell Therapy Platform to Revolutionize the Treatment of Solid Tumors in Select Patients Portfolio News / Karina Tin March 2, 2022 A2 Bio Publishes Key Preclinical Findings Demonstrating Potential of Its Highly Selective Tmod™ Cell Therapy Platform to Revolutionize the Treatment of Solid Tumors in Select Patients Read More »
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results Portfolio News / Karina Tin March 1, 2022 NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results Read More »
